medigraphic.com
ISSN 1025-0298 (Digital)
ISSN 1025-028X (Impreso)

2011, Número 2

Siguiente >>

VacciMonitor 2011; 20 (2)


Actividad Adyuvante del aceite de arroz en la respuesta inmune contra ovoalbúmina

Maciel SIT, Moleta CE, Albuquerque D

Idioma: Ingles.
Referencias bibliográficas: 60
Paginas: 1-5
Archivo PDF: 166.64 Kb.


RESUMEN

Evaluamos al aceite de arroz (AA) como adyuvante para la respuesta inmune de ovoalbúmina (OVA), su depósito y los efectos colaterales posibles en el lugar de la inyección. La inmunización de ratones con OVA emulsionada en aceite de arroz (OVA+AA) tuvo como resultado una respuesta de anticuerpos significativamente mayor que la determinada en ratones inmunizados con OVA soluble. Además, estos altos niveles de anticuerpos se observaron durante seis semanas después de la inmunización. Sin embargo, la acción adyuvante del AA fue significativamente menor a la del adyuvante incompleto de Freund (AIF). En la respuesta inmune secundaria, el patrón de anticuerpos específicos contra OVA, estimulados por AA, fue predominantemente IgG1. A pesar del significativo aumento de la respuesta humoral inducido por AA, no se observaron lesiones en el lugar de la inyección. Además, el análisis histológico mostró que la reacción inmunológica causada por AA fue ligera y temporal, sugiriendo que el AA parece ser una alternativa segura, eficaz y químicamente definida para el AIF en muchas situaciones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Broderson JR. A retrospective review of lesions associated with the use of Freund’s adjuvant. Lab Anim Sci 1989;39:400-5.

  2. Claasen E, Leeuw W, Greve P, Hendriksen C, Boersma W. Freund’s complete adjuvant: an effective but disagreable formula. Res Immunol 1992;143:478-83.

  3. Mbow ML, Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccine, Current Opinion in Immunol 2010;22:411- 6.

  4. Amyx HL. Control of animal pain and distress in antibody production and infectious disease studies. J Am Vet Med Assoc 1987; 191:1287-9.

  5. Lambrecht BN, Kool M, Willart MAM, Hammad H. Mechanism of action of clinically approved adjuvants. Current Opinion in Immunology 2009; 21:23-9.

  6. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends in Immunol 2009;30:23-32.

  7. Moro E, Junqueira JOB. Levantamento da incidência de reações vacinais e/ou medicamentosas em carcaças de bovinos ao abate em frigoríficos no Brasil. A hora Vet 1999;122:74-7.

  8. França AT, Alves GG, Mesquita AJ, Chiquetto CE, Bueno CP, Oliveira ASC. Perdas econômicas por abscessos vacinais e/ ou medicamentosos em carcaças de bovinos abatidos no estado de Goiás. Ciência Animal Brasileira 2006;7(1):93-6.

  9. Hilleman MR, Woodhour AF, Friedman A, Weibel RE, Stokes J. The clinical application of adjuvant-65. Ann Allergy 1972;30:152-8.

  10. Silva ACM, Guerra JL, Melo DF, Lima MS. Adjuvant effect of corn and olive oils in mouse immune response. In: VI Pharmatech, III Annais of the SBTF Annual Meeting. Recife, Brazil: UFPE; 2001. p. 165-6.

  11. Mota EF. Atividade adjuvante dos óleos de amendoim (Arachis hypogaea L), algodão (Gossipium hirsutum L) e arroz (Oryza sativa L) na resposta imune humoral e celular, Ph.D. Thesis, Departamento de Bioquímica e Biología Molecular, Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; 2006.

  12. Moncada C, Torres V, Israel Y. Simple method for the preparation of antigen emulsions for immunization. J Immunol Methods1993;162:133-40.

  13. Becher P. Testing and emulsion properties, Emulsions Theory and Practice, second ed. New York: Reinhold; 1965

  14. Aroeira LS, Cardillo F, De Albuquerque DA, Vaz NM, Mengel J. Anti-IL-10 treatment does not block either the induction or the maintenance of orally induced tolerance to OVA. Scand J Immunol 1995; 41:319-23.

  15. Albuquerque DA, Saxena V, Adams DE, Boivin GP, Brunner HI, Witte DP. et al. An ACE inhibitor reduces Th2 cytokines and TGF-b1 and TGF-b2 isoforms in murine lupus nephritis. Kidney Int 2004;65:846-59.

  16. Snapper CM, Finkelman FD, Paul WE. Regulation of IgG1 and IgE production by interleukin 4. Immunol Rev 2004;102:51-75.

  17. McKenzie GJ, Fallon P, Emsom CL, Grencis R, McKenzie AN. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1999;189:1565-72.

  18. Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. Interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund’s complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996;26:2062-6.

  19. Grun JL, Maurer PH. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 1989;121:134-45.

  20. Silva AS, Cavalcante LT, Faquim-Mauro EL, Macedo MS. Regulation of anaphylactic IgG1 antibody production by IL-4 and IL-10. Int Arch Allergy Immunol 2006;141:70-8.

  21. Broderson JR. A retrospective review of lesions associated with the use of Freund’s adjuvant. Lab Anim Sci 1989;39:400-5.

  22. Claasen E, Leeuw W, Greve P, Hendriksen C, Boersma W. Freund’s complete adjuvant: an effective but disagreable formula. Res Immunol 1992;143:478-83.

  23. Mbow ML, Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccine, Current Opinion in Immunol 2010;22:411- 6.

  24. Amyx HL. Control of animal pain and distress in antibody production and infectious disease studies. J Am Vet Med Assoc 1987; 191:1287-9.

  25. Lambrecht BN, Kool M, Willart MAM, Hammad H. Mechanism of action of clinically approved adjuvants. Current Opinion in Immunology 2009; 21:23-9.

  26. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends in Immunol 2009;30:23-32.

  27. Moro E, Junqueira JOB. Levantamento da incidência de reações vacinais e/ou medicamentosas em carcaças de bovinos ao abate em frigoríficos no Brasil. A hora Vet 1999;122:74-7.

  28. França AT, Alves GG, Mesquita AJ, Chiquetto CE, Bueno CP, Oliveira ASC. Perdas econômicas por abscessos vacinais e/ ou medicamentosos em carcaças de bovinos abatidos no estado de Goiás. Ciência Animal Brasileira 2006;7(1):93-6.

  29. Hilleman MR, Woodhour AF, Friedman A, Weibel RE, Stokes J. The clinical application of adjuvant-65. Ann Allergy 1972;30:152-8.

  30. Silva ACM, Guerra JL, Melo DF, Lima MS. Adjuvant effect of corn and olive oils in mouse immune response. In: VI Pharmatech, III Annais of the SBTF Annual Meeting. Recife, Brazil: UFPE; 2001. p. 165-6.

  31. Mota EF. Atividade adjuvante dos óleos de amendoim (Arachis hypogaea L), algodão (Gossipium hirsutum L) e arroz (Oryza sativa L) na resposta imune humoral e celular, Ph.D. Thesis, Departamento de Bioquímica e Biología Molecular, Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; 2006.

  32. Moncada C, Torres V, Israel Y. Simple method for the preparation of antigen emulsions for immunization. J Immunol Methods1993;162:133-40.

  33. Becher P. Testing and emulsion properties, Emulsions Theory and Practice, second ed. New York: Reinhold; 1965

  34. Aroeira LS, Cardillo F, De Albuquerque DA, Vaz NM, Mengel J. Anti-IL-10 treatment does not block either the induction or the maintenance of orally induced tolerance to OVA. Scand J Immunol 1995; 41:319-23.

  35. Albuquerque DA, Saxena V, Adams DE, Boivin GP, Brunner HI, Witte DP. et al. An ACE inhibitor reduces Th2 cytokines and TGF-b1 and TGF-b2 isoforms in murine lupus nephritis. Kidney Int 2004;65:846-59.

  36. Snapper CM, Finkelman FD, Paul WE. Regulation of IgG1 and IgE production by interleukin 4. Immunol Rev 2004;102:51-75.

  37. McKenzie GJ, Fallon P, Emsom CL, Grencis R, McKenzie AN. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1999;189:1565-72.

  38. Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. Interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund’s complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996;26:2062-6.

  39. Grun JL, Maurer PH. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 1989;121:134-45.

  40. Silva AS, Cavalcante LT, Faquim-Mauro EL, Macedo MS. Regulation of anaphylactic IgG1 antibody production by IL-4 and IL-10. Int Arch Allergy Immunol 2006;141:70-8.

  41. Broderson JR. A retrospective review of lesions associated with the use of Freund’s adjuvant. Lab Anim Sci 1989;39:400-5.

  42. Claasen E, Leeuw W, Greve P, Hendriksen C, Boersma W. Freund’s complete adjuvant: an effective but disagreable formula. Res Immunol 1992;143:478-83.

  43. Mbow ML, Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccine, Current Opinion in Immunol 2010;22:411- 6.

  44. Amyx HL. Control of animal pain and distress in antibody production and infectious disease studies. J Am Vet Med Assoc 1987; 191:1287-9.

  45. Lambrecht BN, Kool M, Willart MAM, Hammad H. Mechanism of action of clinically approved adjuvants. Current Opinion in Immunology 2009; 21:23-9.

  46. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends in Immunol 2009;30:23-32.

  47. Moro E, Junqueira JOB. Levantamento da incidência de reações vacinais e/ou medicamentosas em carcaças de bovinos ao abate em frigoríficos no Brasil. A hora Vet 1999;122:74-7.

  48. França AT, Alves GG, Mesquita AJ, Chiquetto CE, Bueno CP, Oliveira ASC. Perdas econômicas por abscessos vacinais e/ ou medicamentosos em carcaças de bovinos abatidos no estado de Goiás. Ciência Animal Brasileira 2006;7(1):93-6.

  49. Hilleman MR, Woodhour AF, Friedman A, Weibel RE, Stokes J. The clinical application of adjuvant-65. Ann Allergy 1972;30:152-8.

  50. Silva ACM, Guerra JL, Melo DF, Lima MS. Adjuvant effect of corn and olive oils in mouse immune response. In: VI Pharmatech, III Annais of the SBTF Annual Meeting. Recife, Brazil: UFPE; 2001. p. 165-6.

  51. Mota EF. Atividade adjuvante dos óleos de amendoim (Arachis hypogaea L), algodão (Gossipium hirsutum L) e arroz (Oryza sativa L) na resposta imune humoral e celular, Ph.D. Thesis, Departamento de Bioquímica e Biología Molecular, Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; 2006.

  52. Moncada C, Torres V, Israel Y. Simple method for the preparation of antigen emulsions for immunization. J Immunol Methods1993;162:133-40.

  53. Becher P. Testing and emulsion properties, Emulsions Theory and Practice, second ed. New York: Reinhold; 1965

  54. Aroeira LS, Cardillo F, De Albuquerque DA, Vaz NM, Mengel J. Anti-IL-10 treatment does not block either the induction or the maintenance of orally induced tolerance to OVA. Scand J Immunol 1995; 41:319-23.

  55. Albuquerque DA, Saxena V, Adams DE, Boivin GP, Brunner HI, Witte DP. et al. An ACE inhibitor reduces Th2 cytokines and TGF-b1 and TGF-b2 isoforms in murine lupus nephritis. Kidney Int 2004;65:846-59.

  56. Snapper CM, Finkelman FD, Paul WE. Regulation of IgG1 and IgE production by interleukin 4. Immunol Rev 2004;102:51-75.

  57. McKenzie GJ, Fallon P, Emsom CL, Grencis R, McKenzie AN. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1999;189:1565-72.

  58. Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. Interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund’s complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996;26:2062-6.

  59. Grun JL, Maurer PH. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 1989;121:134-45.

  60. Silva AS, Cavalcante LT, Faquim-Mauro EL, Macedo MS. Regulation of anaphylactic IgG1 antibody production by IL-4 and IL-10. Int Arch Allergy Immunol 2006;141:70-8.




2020     |     www.medigraphic.com